Heparin Dosing and Target aPTT for Hypercoagulable States

Initial Dosing Recommendations

For patients with suspected hypercoagulable states, intravenous unfractionated heparin should be administered with a weight-adjusted regimen of 80 IU/kg as an initial bolus followed by 18 IU/kg/hour continuous infusion, with a target aPTT of 1.5-2.5 times the control value (approximately 45-75 seconds) 1, 2, 3
Weight-adjusted dosing is preferred over standard fixed dosing as it achieves therapeutic levels more quickly with fewer fluctuations in aPTT 1
Initial bolus: 80 IU/kg intravenously 2, 3, 4
Maintenance infusion: 18 IU/kg/hour as continuous IV infusion 2, 3, 4

When aPTT results are available, adjust the heparin dose according to the following protocol 5
aPTT <35 seconds (<1.2 times control): Give 80 IU/kg bolus and increase infusion rate by 4 IU/kg/hour 5
aPTT 35-45 seconds (1.2-1.5 times control): Give 40 IU/kg bolus and increase infusion rate by 2 IU/kg/hour 3
aPTT 46-70 seconds (1.5-2.3 times control): No change needed 5
aPTT 71-90 seconds (2.3-3.0 times control): Reduce infusion rate by 2 IU/kg/hour 5
aPTT >90 seconds (>3.0 times control): Stop infusion for 1 hour, then reduce rate by 3 IU/kg/hour 5

An unexpectedly poor response to heparin may suggest pre-existing thrombophilia 1
Patients with hypercoagulable states may require higher doses to achieve therapeutic aPTT levels 1
Monitor platelet counts if heparin is continued beyond 5 days due to risk of heparin-induced thrombocytopenia 1
Consider checking anti-Xa levels in patients with severe renal failure or during pregnancy if using LMWH 5

Continue heparin for at least 5 days while overlapping with oral anticoagulation 6
Warfarin can be started as soon as the diagnosis is confirmed 1
Continue heparin until adequate maintenance anticoagulation with warfarin is achieved (INR 2.0-3.0) 1, 6
Discontinue heparin after at least 5 days of therapy and when INR has been ≥2.0 for at least 24 hours 6

Low molecular weight heparin (LMWH) should be considered as preferable to UFH in stable patients, having equal efficacy and safety while being easier to use 6
For patients with suspected heparin-induced thrombocytopenia, non-heparin anticoagulants such as direct thrombin inhibitors should be used 7

aPTT testing is required only after UFH has been started to guide dose adjustments; baseline PT/INR and aPTT are not needed before the first heparin dose. 8
The first aPTT measurement should be obtained 4–6 hours after the initial heparin bolus. 8
After any dose change, a repeat aPTT should be drawn 6–10 hours later to allow the new dose to reach steady state. 8
Once the aPTT is within the therapeutic range, daily monitoring is sufficient. 8
The target therapeutic range is 1.5–2.5 times the control value (approximately 45–75 seconds). 8

INR monitoring begins after warfarin is started, with a target INR of 2.0–3.0 for acute PE. 8
The INR should be measured every 1–2 days during the initial titration phase. 8

Upon diagnosis of acute PE, weight‑adjusted UFH should be started immediately: a bolus of 80 IU/kg followed by an infusion of 18 IU/kg/h. 8
The first aPTT (drawn 4–6 hours after the bolus) is used to guide subsequent dose adjustments. 8